Cardiovascular events and safety outcomes associated with remdesivir using a World Health Organization international pharmacovigilance database

On October 2020, the US Food and Drug Administration (FDA) approved remdesivir as the first drug for the treatment of coronavirus disease 2019 (COVID‐19), increasing remdesivir prescriptions worldwide. However, potential cardiovascular (CV) toxicities associated with remdesivir remain unknown. We ai...

Descripción completa

Detalles Bibliográficos
Autores principales: Jung, Se Yong, Kim, Min Seo, Li, Han, Lee, Keum Hwa, Koyanagi, Ai, Solmi, Marco, Kronbichler, Andreas, Dragioti, Elena, Tizaoui, Kalthoum, Cargnin, Sarah, Terrazzino, Salvatore, Hong, Sung Hwi, Abou Ghayda, Ramy, Kim, Nam Kyun, Chung, Seo Kyoung, Jacob, Louis, Salem, Joe‐Elie, Yon, Dong Keon, Lee, Seung Won, Kostev, Karel, Kim, Ah Young, Jung, Jo Won, Choi, Jae Young, Shin, Jin Soo, Park, Soon‐Jung, Choi, Seong Woo, Ban, Kiwon, Moon, Sung‐Hwan, Go, Yun Young, Shin, Jae Il, Smith, Lee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8841455/
https://www.ncbi.nlm.nih.gov/pubmed/34719115
http://dx.doi.org/10.1111/cts.13168

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8841455/
https://www.ncbi.nlm.nih.gov/pubmed/34719115
http://dx.doi.org/10.1111/cts.13168

Ejemplares similares